retatrutide gip glp-1 glucagon receptor agonist triple phase 2 trial obesity First-in-Class 'Triple-G'! The dual glucose-dependent insulinotropic polypeptide

Are there any potential harms to someone who has a relatively healthy weight using compounded GLP-1s

Commenters supported ensuring that the PE inputs reflect current medical practice but stressed that any changes must be based on a transparent and rigorous survey process

GLP-1 receptor agonists are prescription medications originally developed for type 2 diabetes that produce significant weight loss

Additionally, the pooled result showed that adding GLP-1 treatment was more effective compared with metformin alone or placebo for improving menstrual frequency

Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity